LivaNova Shareholders Approve Key Incentive Plans at AGM

LivaNova ( (LIVN) ) has issued an announcement.

On June 11, 2025, LivaNova PLC held its Annual General Meeting where shareholders approved two key incentive plans: the Second Amended and Restated 2022 Incentive Award Plan and the 2025 Director Incentive Award Plan. These plans, previously approved by the Board, aim to provide equity-based compensation to executives and directors, with a total of 2,500,000 shares allocated for awards. The AGM also saw the election of ten directors and the approval of various resolutions, including the ratification of PricewaterhouseCoopers LLP as the company’s auditor for 2025, reflecting strong shareholder support for the company’s governance and strategic initiatives.

The most recent analyst rating on (LIVN) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on LivaNova stock, see the LIVN Stock Forecast page.

Spark’s Take on LIVN Stock

According to Spark, TipRanks’ AI Analyst, LIVN is a Neutral.

LivaNova’s stock score is driven by strong financial stability and positive technical momentum, offset by profitability challenges and valuation concerns. The earnings call provides positive growth outlooks, but substantial legal liabilities pose risks. Improving profitability and resolving legal disputes are crucial for future performance.

To see Spark’s full report on LIVN stock, click here.

More about LivaNova

LivaNova PLC operates in the medical technology industry, focusing on innovative solutions for cardiac surgery, neuromodulation, and other medical device sectors.

Average Trading Volume: 798,417

Technical Sentiment Signal: Hold

Current Market Cap: $2.6B

For detailed information about LIVN stock, go to TipRanks’ Stock Analysis page.